"Sanguine estimates the annual worldwide market potential for this product at $20 billion. In
the United States alone nearly everyone who reaches the age of 75 will need blood, plasma,
or one of their components at least once in his lifetime."
Drees, who has been in the forefront of the artificial blood products field for more than 20
years, was the president and CEO of the only company to have obtained FDA approval for a
synthetic blood product to date.
So $20,000,000,000.00 for this product-- annually>.
Discounted at 40% for 20 years = $40,000,000,000.00
$40,000,000,000.00 / 21,000,000 share = $1,900.00 PER SHARE!
But let's do a discount rate of 90%!!!
Then you have $22,000,000,000.00 / 21,000,000 = $1,048.00 per share.....
|
